These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 34710748)
1. Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents. Xu Q; Hu M; Li J; Ma X; Chu Z; Zhu Q; Zhang Y; Zhu P; Huang Y; He G Eur J Med Chem; 2022 Jan; 227():113876. PubMed ID: 34710748 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of Lin G; Xu Q; Li J; Chu Z; Ma X; Zhu Q; Zhao Y; Mo J; Ye W; Shao L; Fang T; He M; Yue S; Dai M J Med Chem; 2024 Mar; 67(5):3358-3384. PubMed ID: 38413367 [TBL] [Abstract][Full Text] [Related]
3. Discovery of novel tryptamine derivatives as GluN2B subunit-containing NMDA receptor antagonists via pharmacophore-merging strategy with orally available therapeutic effect of cerebral ischemia. Quan J; Yang H; Qin F; He Y; Liu J; Zhao Y; Ma C; Cheng M Eur J Med Chem; 2023 May; 253():115318. PubMed ID: 37037139 [TBL] [Abstract][Full Text] [Related]
4. An in-silico investigation based on molecular simulations of novel and potential brain-penetrant GluN2B NMDA receptor antagonists as anti-stroke therapeutic agents. El Fadili M; Er-Rajy M; Ali Eltayb W; Kara M; Imtara H; Zarougui S; Al-Hoshani N; Hamadi A; Elhallaoui M J Biomol Struct Dyn; 2024 Aug; 42(12):6174-6188. PubMed ID: 37428078 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro characterisation of ifenprodil-based fluorescein conjugates as GluN1/GluN2B N-Methyl-D-aspartate receptor antagonists. Dhilly M; Becerril-Ortega J; Colloc'h N; MacKenzie ET; Barré L; Buisson A; Nicole O; Perrio C Chembiochem; 2013 Apr; 14(6):759-69. PubMed ID: 23532918 [TBL] [Abstract][Full Text] [Related]
6. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold. Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308 [TBL] [Abstract][Full Text] [Related]
7. Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents. Zampieri D; Fortuna S; Calabretti A; Romano M; Menegazzi R; Schepmann D; Wünsch B; Collina S; Zanon D; Mamolo MG Eur J Med Chem; 2019 Oct; 180():268-282. PubMed ID: 31319263 [TBL] [Abstract][Full Text] [Related]
8. GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine. Kiss JP; Szasz BK; Fodor L; Mike A; Lenkey N; Kurkó D; Nagy J; Vizi ES Neurochem Int; 2012 Jan; 60(2):170-6. PubMed ID: 22197911 [TBL] [Abstract][Full Text] [Related]
9. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Karakas E; Simorowski N; Furukawa H Nature; 2011 Jun; 475(7355):249-53. PubMed ID: 21677647 [TBL] [Abstract][Full Text] [Related]
10. Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. Yuan H; Myers SJ; Wells G; Nicholson KL; Swanger SA; Lyuboslavsky P; Tahirovic YA; Menaldino DS; Ganesh T; Wilson LJ; Liotta DC; Snyder JP; Traynelis SF Neuron; 2015 Mar; 85(6):1305-1318. PubMed ID: 25728572 [TBL] [Abstract][Full Text] [Related]
11. Mapping the high-affinity binding domain of 5-substituted benzimidazoles to the proximal N-terminus of the GluN2B subunit of the NMDA receptor. Wee XK; Ng KS; Leung HW; Cheong YP; Kong KH; Ng FM; Soh W; Lam Y; Low CM Br J Pharmacol; 2010 Jan; 159(2):449-61. PubMed ID: 20082612 [TBL] [Abstract][Full Text] [Related]
12. The discovery of subunit-selective GluN1/GluN2B NMDAR antagonist via pharmacophere-based virtual screening. Tang J; Jin J; Huang Z; An F; Huang C; Jiang W Exp Biol Med (Maywood); 2023 Dec; 248(24):2560-2577. PubMed ID: 38282535 [TBL] [Abstract][Full Text] [Related]
13. Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent. Lan Z; Xu X; Xu W; Li J; Liang Z; Zhang X; Lei M; Zhao C Drug Des Devel Ther; 2015; 9():3377-91. PubMed ID: 26170623 [TBL] [Abstract][Full Text] [Related]
15. A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists. Stroebel D; Buhl DL; Knafels JD; Chanda PK; Green M; Sciabola S; Mony L; Paoletti P; Pandit J Mol Pharmacol; 2016 May; 89(5):541-51. PubMed ID: 26912815 [TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel GluN2A NMDAR positive allosteric modulators via scaffold hopping strategy as anti-stroke therapeutic agents. Chen X; Zhu H; Liu X; Li Q; Dong M Bioorg Med Chem; 2023 Apr; 83():117236. PubMed ID: 36934527 [TBL] [Abstract][Full Text] [Related]
17. Piroxicam inhibits NMDA receptor-mediated excitotoxicity through allosteric inhibition of the GluN2B subunit: an in silico study elucidating a novel mechanism of action of the drug. Mazumder MK; Borah A Med Hypotheses; 2014 Dec; 83(6):740-6. PubMed ID: 25459147 [TBL] [Abstract][Full Text] [Related]